NCT05525247View on ClinicalTrials.gov

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

December 21, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

January 31, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

SLC-3010

Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle

COMBINATION_PRODUCT

Gemcitabine

1000 ㎎/㎡ IV infusion over 30 minutes on day 1 and 8 of each 21-day cycle

Trial Locations (9)

2298

NOT_YET_RECRUITING

Selecxine Investigator site, Waratah

6153

NOT_YET_RECRUITING

Selecxine Investigator site, Brentwood

13620

NOT_YET_RECRUITING

Selecxine Investigator site, Gyeonggi-do

34232

NOT_YET_RECRUITING

Selecxine Investigator site, Sarasota

48201

RECRUITING

Selecxine Investigator site, Detroit

73104

NOT_YET_RECRUITING

Selecxine Investigator site, Oklahoma City

03080

RECRUITING

Selecxine Investigator site, Seoul

03722

RECRUITING

Selecxine Investigator site, Seoul

05505

RECRUITING

Selecxine Investigator site, Seoul

Sponsors

Lead Sponsor

Selecxine
All Listed Sponsors
lead

Selecxine

INDUSTRY

NCT05525247 - A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination | Biotech Hunter | Biotech Hunter